CAMCEVI KIT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Camcevi Kit, and what generic alternatives are available?
Camcevi Kit is a drug marketed by Accord and is included in one NDA. There are four patents protecting this drug.
This drug has thirty-seven patent family members in eighteen countries.
The generic ingredient in CAMCEVI KIT is leuprolide mesylate. There are twenty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the leuprolide mesylate profile page.
DrugPatentWatch® Generic Entry Outlook for Camcevi Kit
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 16, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CAMCEVI KIT?
- What are the global sales for CAMCEVI KIT?
- What is Average Wholesale Price for CAMCEVI KIT?
Summary for CAMCEVI KIT
| International Patents: | 37 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | CAMCEVI KIT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CAMCEVI KIT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for CAMCEVI KIT
| Drug Class | Gonadotropin Releasing Hormone Receptor Agonist |
| Mechanism of Action | Gonadotropin Releasing Hormone Receptor Agonists |
US Patents and Regulatory Information for CAMCEVI KIT
CAMCEVI KIT is protected by four US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of CAMCEVI KIT is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting CAMCEVI KIT
Pharmaceutical compositions with enhanced stability
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical compositions with enhanced stability
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Pharmaceutical compositions with enhanced stability
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting CAMCEVI KIT
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord | CAMCEVI KIT | leuprolide mesylate | EMULSION;SUBCUTANEOUS | 211488-001 | May 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Accord | CAMCEVI KIT | leuprolide mesylate | EMULSION;SUBCUTANEOUS | 211488-001 | May 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Accord | CAMCEVI KIT | leuprolide mesylate | EMULSION;SUBCUTANEOUS | 211488-001 | May 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CAMCEVI KIT
When does loss-of-exclusivity occur for CAMCEVI KIT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07207618
Patent: Pharmaceutical compositions with enhanced stability
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0706558
Patent: composições farmacêuticas com estabilidade aperfeiçoada
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 37569
Patent: COMPOSITIONS PHARMACEUTIQUES A STABILITE AMELIOREE (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1400363
Patent: Pharmaceutical compositions with enhanced stability
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 84009
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 84009
Patent: COMPOSITIONS PHARMACEUTIQUES A STABILITE AMELIOREE (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 26975
Patent: PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 42415
Estimated Expiration: ⤷ Sign Up
Patent: 09523798
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 08009125
Patent: COMPOSICIONES FARMACEUTICAS CON ESTABILIDAD MEJORADA. (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY.)
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 27383
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ (HIGH STABILITY PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 08129201
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 84009
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1728868
Estimated Expiration: ⤷ Sign Up
Patent: 080089643
Patent: PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY
Estimated Expiration: ⤷ Sign Up
Patent: 150017777
Patent: PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 97712
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 76241
Estimated Expiration: ⤷ Sign Up
Patent: 0831131
Patent: Pharmaceutical compositions with enhanced stability
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering CAMCEVI KIT around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
